LESL vs NBIX · rev $790.4M vs P/E 45, rev $1.77B
Leslies Inc (LESL) versus Neurocrine Biosciences Inc (NBIX) — a side-by-side from cached financials, not a winner call.
Leslies Inc (LESL) is a specialty retail company listed on NASDAQ.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
Latest reported LESL revenue for 2026-07-04 was $790.4M. Net income was -$87.7M. LESL currently screens at market cap $71.9M.
Latest reported NBIX revenue for 2026-06-30 was $1.77B. Net income was $342.3M. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
LESL currently screens at market cap $71.9M. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Not investment advice. Open the LESL and NBIX stock pages for the full models.
Not investment advice.